Company intelligence / Profile preview

EpiCypher

Research Triangle Park, North Carolina, United Statesepicypher.com ↗

Ownership: Private
Development stage: Commercial

Overview

EpiCypher provides advanced tools for epigenetics and chromatin biology research. Their technologies enable high-resolution mapping of protein-DNA interactions and quantitative analysis of chromatin regulation. These products are widely used in academic research as well as drug discovery but do not themselves constitute clinical therapeutics. No direct clinical results reported.

Therapeutic areas: Other
Modalities: Recombinant protein (designer nucleosomes)Assay platform (CUTANA™SNAP-ChIP®dCypher™EpiDyne®)Antibody (for chromatin research)Enzyme (chromatin-modifying enzymes)
Industry: Non-Drug Biotech

Partnerships

Collaborations with academic labs at MD Anderson Cancer Center, Stanford University, UNC Chapel Hillpartnerships with industry clients for custom assay development.

Beyond the preview

Go deeper on EpiCypher.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiCypher.

Explore the full profile